Top

Published in:

Open Access 01-06-2016

The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary

Authors: Cornelie D. Andela, Margreet Scharloo, Steven Ramondt, Jitske Tiemensma, Olga Husson, Sofia Llahana, Alberto M. Pereira, Ad. A. Kaptein, Noëlle G. A. Kamminga, Nienke R. Biermasz

Published in: Pituitary | Issue 3/2016

Abstract

Background

Patients report persisting impairment in quality of life (QoL) after treatment for pituitary disease. At present, there is no questionnaire to assess (a) whether patients with pituitary disease are bothered by these consequences, and (b) their needs for support.

Objective

To develop and validate a disease-specific questionnaire for patients with pituitary disease which incorporates patient perceived bother related to the consequences of the disease, and their needs for support.

Methods

Items for the Leiden Bother and Needs Questionnaire for patients with pituitary disease (LBNQ-Pituitary) were formulated based on results of a recent focus group study (n = 49 items). 337 patients completed the LBNQ-Pituitary and six validated QoL questionnaires (EuroQoL-5D, SF-36, MFI-20, HADS, AcroQol, CushingQoL). Construct validity was examined by exploratory factor analysis. Reliabilities of the subscales were calculated with Cronbach’s alphas, and concurrent validity was assessed by calculating Spearman’s correlations between the LBNQ-Pituitary and the other measures.

Results

Factor analyses produced five subscales (i.e., mood problems, negative illness perceptions, issues in sexual functioning, physical and cognitive complaints, issues in social functioning) containing a total of 26 items. All factors were found to be reliable (Cronbach’s alphas all ≥.765), and the correlations between the dimensions of the LBNQ-Pituitary and other questionnaires (all P ≤ .0001) demonstrated convergent validity.

Conclusions

The LBNQ-Pituitary can be used to assess the degree to which patients are bothered by the consequences of the pituitary disease, as well as their needs for support. It could also facilitate an efficient assessment of patients’ needs for support in clinical practice. We postulate that paying attention to needs for support will lead to optimal patient care (e.g., improvement in psychosocial care), and positively affect QoL.

Available only for authorised users

Gardner D, Shoback D (2011) Basic and clinical endocrinology, 9th edn. McGrawHill, Singapore, pp 100–101

Johnson MD, Woodburn CJ, Vance ML (2003) Quality of life in patients with a pituitary adenoma. Pituitary 6:81–87CrossRefPubMed

Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89:5369–5376CrossRefPubMed

Dekkers OM, van der Klaauw AA, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, Smit JW, Romijn JA (2006) Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91:3364–3369CrossRefPubMed

Kars M, van der Klaauw AA, Onstein CS, Pereira AM, Romijn JA (2007) Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol 157:133–139CrossRefPubMed

van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW, Romijn JA (2005) Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 90:3279–3286CrossRefPubMed

Andela CD, Scharloo M, Pereira AM, Kaptein AA, Biermasz NR (2015) Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18:752–776CrossRefPubMed

Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T (2012) The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties. Clin Endocrinol (Oxf) 76:851–860CrossRef

Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T (2012) The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part II: normative data from 1784 healthy people. Clin Endocrinol (Oxf) 76:861–867CrossRef

10.

Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE (2008) Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 158:623–630CrossRefPubMed

11.

Badia X, Webb SM, Prieto L, Lara N (2004) Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2:13CrossRefPubMedPubMedCentral

12.

Webb SM, Badia X, Surinach NL (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155:269–277CrossRefPubMed

13.

Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, Lucas T, Paramo C, Pico A, Lucas A, Halperin I, Obiols G, Astorga R (2002) Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57:251–258CrossRef

14.

McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L, Wiren L (1999) The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 8:373–383CrossRefPubMed

15.

Andela CD, Niemeijer ND, Scharloo M, Tiemensma J, Kanagasabapathy S, Pereira AM, Kamminga NG, Kaptein AA, Biermasz NR (2014) Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. Pituitary 18:86–100CrossRef

16.

Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA, Pereira AM, Romijn JA (2010) Subtle cognitive impairments in patients with long-term cure of Cushing’s disease. J Clin Endocrinol Metab 95:2699–2714CrossRefPubMed

17.

Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976–981CrossRefPubMed

18.

Weigold A, Weigold IK, Russell EJ (2013) Examination of the equivalence of self-report survey-based paper-and-pencil and internet data collection methods. Psychol Methods 18:53–70CrossRefPubMed

19.

Ellgring H, Seiler S, Perleth B, Frings W, Gasser T, Oertel W (1993) Psychosocial aspects of Parkinson’s disease. Neurology 43:S41–S44CrossRefPubMed

20.

Spliethoff-Kamminga NG, Zwinderman AH, Springer MP, Roos RA (2003) Psychosocial problems in Parkinson’s disease: evaluation of a disease-specific questionnaire. Mov Disord 18:503–509CrossRefPubMed

21.

EuroQoL group (1990) EuroQol—a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16:199–208CrossRef

22.

Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, Westlake L (1992) Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305:160–164CrossRefPubMedPubMedCentral

23.

Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483CrossRefPubMed

24.

Smets EM, Garssen B, Bonke B, De Haes JC (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315–325CrossRefPubMed

25.

Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52:69–77CrossRefPubMed

26.

Snaith RP, Zigmond AS (1986) The Hospital Anxiety and Depression Scale. Br Med J (Clin Res Ed) 292:344CrossRef

27.

Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, van Hemert AM (1997) A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 27:363–370CrossRefPubMed

28.

Santos A, Resmini E, Martinez-Momblan MA, Crespo I, Valassi E, Roset M, Badia X, Webb SM (2012) Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice. Eur J Endocrinol 167:337–342CrossRefPubMed

29.

Hutcheson G, Sofroniou N (2009) The multivariate social scientist, 1999. In: Field A (ed) Discovering statistics using SPSS, 2nd edn. Sage Publications, London, p 659

30.

Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing’s syndrome. Eur J Endocrinol 165:527–535CrossRefPubMed

31.

Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab 96:3550–3558CrossRefPubMed

32.

Scharloo M, Kaptein AA, Schlosser M, Pouwels H, Bel EH, Rabe KF, Wouters EF (2007) Illness perceptions and quality of life in patients with chronic obstructive pulmonary disease. J Asthma 44:575–581CrossRefPubMed

33.

Kaptein AA, Scharloo M, Helder DI, Snoei L, van Kempen GM, Weinman J, van Houwelingen JC, Roos RA (2007) Quality of life in couples living with Huntington’s disease: the role of patients’ and partners’ illness perceptions. Qual Life Res 16:793–801CrossRefPubMedPubMedCentral

34.

Engel GL (1977) The need for a new medical model: a challenge for biomedicine. Science 196:129–136CrossRefPubMed

35.

van der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP, van Aken MO, Havekes B, Pereira AM, Pijl H, Smit JW, Romijn JA (2008) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol (Oxf) 69:775–784CrossRef

36.

Baird A, Sullivan T, Zafar S, Rock J (2003) Quality of life in patients with pituitary tumors: a preliminary study. Qual Manag Health Care 12:97–105CrossRefPubMed

37.

Akechi T, Okuyama T, Endo C, Sagawa R, Uchida M, Nakaguchi T, Akazawa T, Yamashita H, Toyama T, Furukawa TA (2011) Patients’ perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. Psychooncol 20:497–505CrossRef

Title: The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary
Authors: Cornelie D. Andela
Margreet Scharloo
Steven Ramondt
Jitske Tiemensma
Olga Husson
Sofia Llahana
Alberto M. Pereira
Ad. A. Kaptein
Noëlle G. A. Kamminga
Nienke R. Biermasz
Publication date: 01-06-2016
Publisher: Springer US
Published in: Pituitary / Issue 3/2016
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-016-0707-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary

Abstract

Background

Objective

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

Endoscopic transsellar approach to pituitary adenomas with cavernous sinus invasion: Is this just a matter of lateral extension?

Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

Three-dimensional volumetric measurements in defining endoscope-guided giant adenoma surgery outcomes

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

Suprasellar granular cell tumor of the neurohypophysis: surgical outcome of a very rare tumor

Magnetic resonance elastography detects tumoral consistency in pituitary macroadenomas

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page